Canadian Atrial Fibrillation Anticoagulation Study - CAFA

Description:

The Canadian Atrial Fibrillation Anticoagulation Study (CAFA) was a randomized trial of warfarin versus placebo for the primary prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). The trial had planned enrollment of 630 subjects with average follow-up of 2.5 years, but was terminated early after randomizing 383 subjects, due to the interim publication of two major studies supporting the safety and efficacy of warfarin for this indication.